A medical oncologist outlines several core requirements of CGP, including coverage of all actionable treatment options, guidance of clinical trials, and prognosis insights. They believe CGP usage has evolved over the years, expanding to include more genes and improved treatment options, and they expect CGP to be increasingly utilized in neoadjuvant settings as more medications and clinical trials become available. However, there remain significant challenges and pain points associated with CGP testing, such as turnaround time for tissue testing and cost issues. There is a possibility of bringing CGP testing in-house if faster turnaround times or equivalent tests are available. They also highlight the potential role of liquid biopsy in the future, especially for high-shedding diseases. They mention that reducing the cost and improving insurance coverage will be important for wider adoption of CGP testing.
PDF deck with summarized feedback from stakeholders
Individual PDFs of call transcripts with stakeholders
This package includes both the PDF deck and transcripts, providing a comprehensive understanding of stakeholders' views. You will receive a summarized report in the form of a PDF deck, as well as the full transcript of the discussions.
Individual call transcript of a single stakeholder discussing their views. This option is ideal for those who are interested in a specific stakeholder's perspective and insights on the topic.